Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of ⁠the therap...

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

The AI major’s half a dozen deals in the first quarter underscore its push to strengthen its position across enterprise software, developer...

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...

Foundayo Eli Lilly weight loss pill: Eli Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral m...

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...

NVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...

NVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...

Novo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheime...

Pfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO....

NVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...

Novo Nordisk has a new CEO. Maziar Mike Doustdar takes the helm. This follows the departure of Lars Fruergaard Jorgensen. The company aims ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...